These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14602748)

  • 1. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    Fisac C; Virgili N; Ferrer E; Barbera MJ; Fumero E; Vilarasau C; Podzamczer D
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5186-92. PubMed ID: 14602748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
    Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
    Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
    J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).
    Casado A; Badia X; Consiglio E; Ferrer E; González A; Pedrol E; Gatell JM; Azuaje C; Llibre JM; Aranda M; Barrufet P; Martínez-Lacasa J; Podzamczer D;
    HIV Clin Trials; 2004; 5(3):132-9. PubMed ID: 15248137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
    Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
    Merry C; Barry MG; Mulcahy F; Ryan M; Tjia JF; Halifax KL; Breckenridge AM; Back DJ
    AIDS; 1998 Jul; 12(10):1163-7. PubMed ID: 9677165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
    Tebas P; Yarasheski K; Henry K; Claxton S; Kane E; Bordenave B; Klebert M; Powderly WG
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):589-94. PubMed ID: 15242534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
    Fisac C; Fumero E; Crespo M; Roson B; Ferrer E; Virgili N; Ribera E; Gatell JM; Podzamczer D
    AIDS; 2005 Jun; 19(9):917-25. PubMed ID: 15905672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
    Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
    Negredo E; Ribalta J; Paredes R; Ferré R; Sirera G; Ruiz L; Salazar J; Reiss P; Masana L; Clotet B
    AIDS; 2002 Jul; 16(10):1383-9. PubMed ID: 12131215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
    Skowron G; Leoung G; Hall DB; Robinson P; Lewis R; Grosso R; Jacobs M; Kerr B; MacGregor T; Stevens M; Fisher A; Odgen R; Yen-Lieberman B
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):351-8. PubMed ID: 15097151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
    van der Valk M; Kastelein JJ; Murphy RL; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato RK; Molhuizen HO; Reiss P;
    AIDS; 2001 Dec; 15(18):2407-14. PubMed ID: 11740191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.
    Padmapriyadarsini C; Ramesh K; Sekar L; Ramachandran G; Reddy D; Narendran G; Sekar S; Chandrasekar C; Anbarasu D; Wanke C; Swaminathan S
    Indian J Med Res; 2017 May; 145(5):641-650. PubMed ID: 28948955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.